Osteoporosis Update

Journal of Midwifery and Women's Health

Volumn 56, Issue 6, 2011, Pages 615-627

  Schuiling, Kerri Durnell ^a   Robinia, Kristi ^a   Nye, Rachel ^a  

^a NORTHERN MICHIGAN UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Bone mass density; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID PLUS COLECALCIFEROL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE PLUS RISEDRONIC ACID; DENOSUMAB; ESTROGEN; GLUCOCORTICOID; IBANDRONIC ACID; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ABDOMINAL PAIN; ALLERGIC REACTION; ARTHRALGIA; BONE DENSITOMETRY; BONE TURNOVER; BREAST CANCER; CHILL; CONSTIPATION; CYSTITIS; DIARRHEA; DIET THERAPY; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; ESOPHAGUS HEMORRHAGE; ESOPHAGUS PERFORATION; ESOPHAGUS ULCER; EYE INFLAMMATION; FEMUR SUBTROCHANTERIC FRACTURE; FEVER; FLATULENCE; FLU LIKE SYNDROME; FRAGILITY FRACTURE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; INFECTION; JAW OSTEONECROSIS; LEG CRAMP; LIFESTYLE MODIFICATION; LIMB PAIN; LUNG EMBOLISM; MUSCLE CRAMP; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NONHUMAN; NOSE IRRITATION; NUTRITIONAL ASSESSMENT; NUTRITIONAL HEALTH; NUTRITIONAL REQUIREMENT; ORTHOSTATIC HYPOTENSION; OSTEOLYSIS; OSTEOPOROSIS; PANCREATITIS; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT ATTITUDE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING TEST; SIDE EFFECT; SKIN MANIFESTATION; SMOKING; STOMACH IRRITATION; TASTE DISORDER; THROMBOEMBOLISM; TREATMENT OUTCOME; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; VOMITING;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HEALTH BEHAVIOR; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 80855131772     PISSN: 15269523     EISSN: 15422011     Source Type: Journal    
DOI: 10.1111/j.1542-2011.2011.00135.x     Document Type: Review

References (63)

1. Komadina R. Hip, osteoporosis: new paradigm. Eur J Trauma Emerg Surg. 2008;2:163-170.
2. Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol. 2006;194:S3-S11.
3. Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R. Screening for osteoporosis: an update for the U.S. preventive services task force. Ann Intern Med. 2010;153(2):1-24.
4. World Health Organization Scientific Group. WHO Technical Report Series 921. Prevention and Management of Osteoporosis. Geneva, Switzerland: World Health Organization; 2003.
5. Wynne AL. Hormone replacement therapy and osteoporosis. In: Wynne A, Woo T, Olyaei A, eds. Pharmacotherapeutics for Nurse Practitioner Prescribers. 2nd ed. Philadelphia, PA: E.A. Davis; 2007:1045-1068.
6. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Dept of Health and Human Services, Office of the Surgeon General; 2004.
7. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: U.S. Government Printing Office; 2010.
8. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. 2002. Accessed April 10, 2011.
9. North American Menopause Society. Position statement: management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010;17(1):25-54.
10. International Osteoporosis Foundation. Updated 2010. Accessed October 8, 2011.
11. Raisz, L. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115(12):3318-3325.
12. Richmond, B. DXA scanning to diagnose osteoporosis: Do you know what the results mean? Cleve Clin J Med. 2003;70(4):353-360.
13. Qaseem A, Snow V, Shekelle P, Hopkins R, Forciea MA, Owens, DK. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149(6):404-415.
14. Hamdy RC, Baim S, Broy SB, et al. Algorithm for the management of osteoporosis. South Med J. 2010;103(10):1009-1015.
15. Neustadt ND, Pieczenik S. Osteoporosis: beyond bone mineral density (part I). Integrative Med. 2008;7:34-38.
16. Goulding PM, Hudson SL. Osteoporosis: the Brittle Bone Disease. Lakeway, TX: National Center of Continuing Education, Inc; 2008:19-36.
17. American College of Obstetricians & Gynecologists Web site. American College of Obstetricians and Gynecologists education pamphlet AP048. Updated December 2007. Accessed November 10, 2010.
18. Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporo Int. 2008;19:399-428.
19. Zmuda J, Sheu Y, Moffett S. The search for human osteoporosis genes. J Musculoskelet Neuronal Interact. 2006;6(1):3-15.
20. Sadler C, Huff M. African-American women, health beliefs, lifestyle and osteoporosis. Orthop Nurs. 2007;26(2):96-103.
21. Society for Adolescent Medicine. A position paper of the society for adolescent medicine. Depot medroxyprogesterone acetate and bone mineral density in adolescents-the black box warning. J Adolesc Health. 2006;39:296-301.
22. Depo-Provera CI [label]. Pharmacia and Upjohn Company division of Pfizer, NY; October 2010. U.S. Food and Drug Administration Web site. Accessed March 15, 2011.
23. Rahman M, Berenson A. Predictors of higher bone mineral density loss and use of depot medroxyprogesterone acetate. Obstet Gynecol. 2010;115(1):35-40.
24. Cromer B, Bonny A, Stager M, et al. Bone mineral density in adolescent females using injectable or oral contraceptives: a 24 month prospective study. Ferti Steril. 2008;90(6):2060-2067.
25. Dore, R. How to prevent glucocorticoid-induced osteoporosis. Cleve Clin J Med. 2010;77(8):529-536.
26. Knudtson, M. Osteoporosis: background and overview. J Nurse Pract. 2009;5(6)(suppl 1):S4-S12.
27. Nordin C. Screening for osteoporosis: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2011;155(4):276.
28. Nelson LM. Menstrual cycle in adolescents: a vital sign of bone health. Contemp OB GYN. 2010:32-37.
29. Nieves JW. Osteoporosis: the role of micronutrients. Am J Clin Nutr. 2005;81:1232S-1239S.
30. Cranney A, Weiler H, ODonnell S, Puil L. Summary of evidence-based review on vitamin D efficacy and safety in relation to bone health. Am J Clin Nutr. 2008;88:513S-519S.
31. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, Hughes-Dawson B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006;84:18-28.
32. Heaney RP. Nutrition and osteoporosis. In: Deng H, Liu Y, eds. Current Topics in Osteoporosis. Singapore: World Scientific Publishing Co. Pte, Ltd;2005:67-117.
33. Reference intakes for calcium and Vitamin-D. Institute of Medicine Web site. Updated 2010. October 9, 2011.
34. Office of Dietary Supplements: Dietary supplements fact sheet. National Institute of Health Web site. Updated November 30, 2010. Accessed January 2, 2011.
35. Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children and adolescents. Pediatrics. 2008;122(5):1142-1152.
36. Hamilton CJ, Swan VJ, Jamal SA. Effects of exercise and physical activity participation on bone mass and geometry in postmenopausal women: a systematic review of pQCT studies. Osteoporo Int. 2010;21:11-23.
37. Cotte F-E, Fardellone P, Mercier F, Gaudin A-F, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporo Int. 2010;21:145-155.
38. Miller PD. All bisphosphonates are (or may not be) the same: potential reasons for clinical differences. J Womens Health. 2010;19(4):665-669.
39. Papapoulos SE. Bisphosphonates: How do they work? Best Pract Res Clin Endocrinol Metab. 2008;22(5):831-847.
40. Simon JA. Are all bisphosphonates the same? Potential reasons for clinical differences: a perspective. J Womens Health. 2010;19(4):719-727.
41. Carroll NA, Davis Doughty SE, Rousseau E, Brucker MC. The mature woman. In: King TL, Brucker MC, eds. Pharmacology for Women's Health. Sundbury, MA: Jones and Bartlett; 2011:1003-1042.
42. Holmes JT, Lee C. Extended interval bisphosphonate dosing: a focus on zoledronic acid (Reclast A)®. Evidence-Based Practice. 2009;12(9):14-15.
43. Fosamax [label]. Merck Sharp & Dome Corp; Whitehouse Station, NJ; March 2010. U.S. Food and Drug Administration Web site. Accessed January 3, 2011.
44. Actonel [label]. Procter & Gamble Pharmaceuticals; Cincinnati, OH; December 2009. U.S. Food and Drug Administration Web site. Accessed January 3, 2011.
45. Boniva [label]. Roche Pharmaceuticals; Nutley, NJ; January 2010. U.S. Food and Drug Administration Web site. Accessed January 3, 2011.
46. Reclast [label]. Novartis Pharmaceuticals Corporation; Stein, Switzerland; May, 2009. U.S. Food and Drug Administration Web site. Accessed January 3, 2011.
47. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213.
48. Black DM, Schwartz AV, Ensrud KE, et al. FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927-2938.
49. Kennel KA, Drake MT. Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clinic Proc. 2009;84(7):632-638.
50. Khosla S, Burr D, Cauley J, et al. Bisphosphonate associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research [editorial]. J Bone Miner Res. 2007;22(10):1479-1491.
51. Pickett FA. Evidence for practice: update on recommendations and issues for managing care of individuals with a history of taking oral bisphosphonates. Can J Dental Hygiene. 2010;44(1):13-19.
52. Black DM, Pierre DD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809-1822.
53. Update of safety review follow-up to the October 1, 2007 early communication about the ongoing safety review of bisphosphonates. U.S. Food and Drug Administration Web site. Updated November 12, 2008. Accessed October 9, 2011.
54. FDA drug safety communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures. U.S. Food and Drug Administration Web site. Updated October 13, 2010. Accessed November 10, 2010.
55. Evista [label]. Indianapolis, IN: Eli Lilly and Company; July 2007. U.S. Food and Drug Administration Web site. Accessed January 3, 2011.
56. Calcitonin [label]. Minneapolis, MN: Upsher-Smith Laboratories Inc; June 2009. U.S. Food and Drug Administration Web site. Accessed January 3, 2011.
57. Forteo [label]. Indianapolis, IN: Eli Lilly and Company; July 2009. U.S. Food and Drug Administration Web site. Accessed January 3, 2011.
58. Prolia [label]. Thousand Oaks, CA: Amgen, 2010. U.S. Food and Drug Administration Web site. Accessed January 3, 2011.
59. Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96(23):1751-1761.
60. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
61. Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756-765.
62. North American Menopause Society. Estrogen and progesterone use in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010;17: 242-255.
63. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy. J Clin Endocrinol Metab. 2010;95(suppl 1):S1-S66.